ZA200505321B - Topical stabilized prostaglandin E compound dosage forms - Google Patents

Topical stabilized prostaglandin E compound dosage forms Download PDF

Info

Publication number
ZA200505321B
ZA200505321B ZA200505321A ZA200505321A ZA200505321B ZA 200505321 B ZA200505321 B ZA 200505321B ZA 200505321 A ZA200505321 A ZA 200505321A ZA 200505321 A ZA200505321 A ZA 200505321A ZA 200505321 B ZA200505321 B ZA 200505321B
Authority
ZA
South Africa
Prior art keywords
dosage form
prostaglandin
compound
group
accordance
Prior art date
Application number
ZA200505321A
Other languages
English (en)
Inventor
Mo Y Joseph
Daniel W Frank
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of ZA200505321B publication Critical patent/ZA200505321B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200505321A 2003-01-03 2005-06-30 Topical stabilized prostaglandin E compound dosage forms ZA200505321B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/336,481 US6841574B2 (en) 2003-01-03 2003-01-03 Topical stabilized prostaglandin E compound dosage forms

Publications (1)

Publication Number Publication Date
ZA200505321B true ZA200505321B (en) 2006-04-26

Family

ID=32681022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505321A ZA200505321B (en) 2003-01-03 2005-06-30 Topical stabilized prostaglandin E compound dosage forms

Country Status (16)

Country Link
US (1) US6841574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1585483B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006514068A (cg-RX-API-DMAC7.html)
KR (2) KR101174788B1 (cg-RX-API-DMAC7.html)
CN (1) CN100574763C (cg-RX-API-DMAC7.html)
AT (1) ATE468098T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003300113B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317924A (cg-RX-API-DMAC7.html)
CA (1) CA2512015C (cg-RX-API-DMAC7.html)
DE (1) DE60332656D1 (cg-RX-API-DMAC7.html)
DK (1) DK1585483T3 (cg-RX-API-DMAC7.html)
ES (1) ES2343246T3 (cg-RX-API-DMAC7.html)
IL (1) IL169425A (cg-RX-API-DMAC7.html)
PT (1) PT1585483E (cg-RX-API-DMAC7.html)
WO (1) WO2004062632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505321B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
CA2848397C (en) 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2019142015A1 (es) * 2018-01-18 2019-07-25 Caicedo Pinto, David Felipe Composicion farmaceutica para la disfuncion erectil de administracion transdermica via uretral en gotas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883576A (en) * 1971-02-02 1975-05-13 Upjohn Co Prostaglandin E{HD 3 {B analogs
US3826823A (en) * 1972-09-25 1974-07-30 Syntex Inc Stabilized prostaglandin preparations
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US5017382A (en) * 1979-03-21 1991-05-21 National Research Development Corporation Controlled release compositions (II)
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
JPS5948409A (ja) * 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
IE59361B1 (en) * 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
SE9501670L (sv) * 1995-05-05 1996-06-10 Perstorp Ab Omläggningsset
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6593369B2 (en) * 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
IL140475A0 (en) * 1998-06-25 2002-02-10 Lavipharm Lab Inc A device and method for the treatment of erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제

Also Published As

Publication number Publication date
CN100574763C (zh) 2009-12-30
CN1756532A (zh) 2006-04-05
PT1585483E (pt) 2010-06-17
US20040131664A1 (en) 2004-07-08
ATE468098T1 (de) 2010-06-15
JP2006514068A (ja) 2006-04-27
EP1585483A4 (en) 2006-04-19
US6841574B2 (en) 2005-01-11
CA2512015A1 (en) 2004-07-29
WO2004062632A1 (en) 2004-07-29
JP5395138B2 (ja) 2014-01-22
JP2012036196A (ja) 2012-02-23
AU2003300113A1 (en) 2004-08-10
KR20050098853A (ko) 2005-10-12
AU2003300113B2 (en) 2010-03-11
EP1585483B1 (en) 2010-05-19
BR0317924A (pt) 2005-11-29
KR101174788B1 (ko) 2012-08-20
HK1090293A1 (zh) 2006-12-22
EP1585483A1 (en) 2005-10-19
CA2512015C (en) 2011-11-08
DE60332656D1 (de) 2010-07-01
ES2343246T3 (es) 2010-07-27
IL169425A (en) 2010-11-30
DK1585483T3 (da) 2010-07-19
KR20110042138A (ko) 2011-04-22

Similar Documents

Publication Publication Date Title
JP5395138B2 (ja) 局所安定化プロスタグランジンe化合物剤形
US6046244A (en) Topical compositions for prostaglandin E1 delivery
JP2014055144A (ja) 局所安定化プロスタグランジンe化合物剤形
CA2665611C (en) Stabilized prostaglandin e composition
AU2014201174B2 (en) Stabilized prostaglandin e composition
HK1090293B (en) Topical stabilized prostaglandin e compound dosage forms